Laddar...
Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma
BACKGROUND: Paclitaxel has significant single agent activity in urothelial cancer. The 130 nm albumin bound paclitaxel (nab-paclitaxel, ABI-007) delivers more paclitaxel to tumor than conventional paclitaxel without cremophor related toxicities. We assessed the efficacy of nab-paclitaxel in combinat...
Sparad:
| I publikationen: | Invest New Drugs |
|---|---|
| Huvudupphovsmän: | , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2013
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5108360/ https://ncbi.nlm.nih.gov/pubmed/24318901 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-0054-5 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|